Clinical Trial Update: Relative Bioavailability Study of CX2101A for the Treatment of COVID-19 [Phase 1]

View source ↗

Summary

Phase 1 relative bioavailability study of CX2101A for COVID-19 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infection

Drugs mentioned

• CX2101A

Snippet

Sponsor: Heronova Pharmaceuticals | Conditions: COVID-19, Coronavirus Infection | Phase 1 | Status: COMPLETED